MDT

96.58

+0.01%↑

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

MDT

96.58

+0.01%↑

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

MDT

96.58

+0.01%↑

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

MDT

96.58

+0.01%↑

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

MDT

96.58

+0.01%↑

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

Home・Aandelen Lijst・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Open

SectorGezondheidszorg

44.8 2.17

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

43.52

Max

46.22

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.2M -91M
Winstmarge	-867.293
Werknemers	316
EBITDA	4M -90M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+23.98% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	196M 3.4B
Vorige openingsprijs	42.63
Vorige sluitingsprijs	44.8

Nieuwssentiment

By Acuity

50%

151 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.81 / 38.24 Steun & Weerstand

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 dec 2025, 23:49 UTC

Acquisities, Fusies, Overnames

WiseTech to Sell Expedient to Appease Competition Regulator

30 dec 2025, 17:12 UTC

Belangrijke Marktbewegers

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

30 dec 2025, 21:16 UTC

Acquisities, Fusies, Overnames

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30 dec 2025, 21:08 UTC

Marktinformatie

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30 dec 2025, 20:41 UTC

Marktinformatie

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30 dec 2025, 20:37 UTC

Winsten

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30 dec 2025, 19:29 UTC

Marktinformatie

Corn Extends Pullback in Light Trade -- Market Talk

30 dec 2025, 18:29 UTC

Marktinformatie

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

30 dec 2025, 16:20 UTC

Winsten

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30 dec 2025, 16:18 UTC

Acquisities, Fusies, Overnames

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30 dec 2025, 16:10 UTC

Marktinformatie

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30 dec 2025, 15:24 UTC

Marktinformatie

Australian Dollar Could Rise Versus Sterling -- Market Talk

30 dec 2025, 15:10 UTC

Acquisities, Fusies, Overnames

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30 dec 2025, 14:24 UTC

Acquisities, Fusies, Overnames

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30 dec 2025, 14:22 UTC

Acquisities, Fusies, Overnames

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30 dec 2025, 14:20 UTC

Acquisities, Fusies, Overnames

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30 dec 2025, 14:17 UTC

Acquisities, Fusies, Overnames

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30 dec 2025, 14:16 UTC

Acquisities, Fusies, Overnames

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30 dec 2025, 14:14 UTC

Acquisities, Fusies, Overnames

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30 dec 2025, 14:12 UTC

Acquisities, Fusies, Overnames

LVMH: Les Editions Croque Futur Is a French Publishing House

30 dec 2025, 14:10 UTC

Acquisities, Fusies, Overnames

LVMH Acquires Les Editions Croque Futur

30 dec 2025, 13:49 UTC

Acquisities, Fusies, Overnames

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30 dec 2025, 13:36 UTC

Marktinformatie

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30 dec 2025, 13:30 UTC

Marktinformatie

Crude Futures Gain in Light Holiday Trade -- Market Talk

30 dec 2025, 12:55 UTC

Marktinformatie

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30 dec 2025, 11:55 UTC

Marktinformatie

Winsten

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30 dec 2025, 11:47 UTC

Winsten

Acquisities, Fusies, Overnames

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30 dec 2025, 11:35 UTC

Acquisities, Fusies, Overnames

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

23.98% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 54.96 USD 23.98%

Hoogste 65 USD

Laagste 44 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Xenon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

151 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.